Genzyme's Ceredase
Executive Summary
Average cost of drug per patient per year is $140,000 "and that is declining," firm says in April 2 statement taking issue with estimates made by Rep. Stark (D-Calif.) in introduction to his orphan drug windfall profit tax bill. Genzyme expects that average maintenance therapy with Ceredase will cost under $60,000 per patient annually. Currently, about 800 patients are being treated with the drug, firm says.